AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05613387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo (ZP8396)
Description: Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin).
Study NCT06454994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyebrow lift
Description: Upper face lifting
Study NCT06454994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyebrow lift
Description: Upper face lifting
Study NCT06454994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jaw lift
Description: Mid-face and low-face lifting
Study NCT06454994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaw lift
Description: Mid-face and low-face lifting
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Transurethral Ultrasound Ablation
Description: Undergo MRI-Guided TULSA
Study NCT05438563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05438563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo DRE
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET
Study NCT05438563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI
Study NCT05131269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 15 % in Water
Description: A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
Study NCT05131269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 20 mL Injection
Description: A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
Study NCT05017103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given IV
Study NCT04551404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)
Description: The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
Study NCT04551404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)
Description: The study intervention consists of a bilateral tRNS application over temporal regions
Study NCT06042413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized CPC Prehabilitation
Description: Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
Study NCT06042413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
Study NCT06042413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
Study NCT06042413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Exercise
Description: Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
Study NCT06042413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Social Support
Description: Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program.
Study NCT06042413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Bundle Interventions
Description: Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit >30, MAP >70, and anesthetic BIS >50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
Study NCT06042413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-operative Standard of Care
Description: Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
Study NCT06042413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative Standard of Care
Description: Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
Study NCT06042413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative Standard of Care
Description: This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
Study NCT06042413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative Standard of Care
Description: This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
Study NCT05404724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole、 SHR0302 tablets
Description: Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
Study NCT04821024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
Study NCT05557500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repitetive transcranial magnetic stimulation
Description: Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
Study NCT06311344 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular biology analyses
Description: Samples of M. perstans microfilariae will be processed by PCR to investigate the presence (or absence) of Wolbachia using a set of primers targeting the genes ftsZ and 16S and optimized using reference material during the first year of the study. Samples of Schistosoma eggs from urine and feces will be processed for DNA extraction. Each sample will be genetically characterised by multi locus analysis of the mitochondrial cox1 region and the nuclear ITS and 18S rRNA regions. PCR products will be analysed by agarose gel electrophoresis and selected amplicons will be purified and Sanger sequenced. For the individuation of Schistosoma hybrids, the nuclear DNA for each sample will be confirmed by analysis of the species-specific polymorphic positions of the ITS1+2 and 18S. The mitochondrial and nuclear DNA genetic profiles for each individual sample will be recorded to determine the species involved in the infections and also any hybrid schistosomes
Study NCT04927247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclacumab
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Study NCT04927247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
Study NCT05218070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EgyVax Vaccine Candidate
Description: EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
Study NCT05218070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml Saline (0.9%)
Study NCT04599504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (Medication)
Description: Medication will be taken daily in pill form.
Study NCT04599504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.
Study NCT06584357 — intervention group
Intervention type: OTHER
Intervention: Biomarker Data Collection
Description: During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
Study NCT06584357 — intervention group
Intervention type: RADIATION
Intervention: MK6240
Description: Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
Study NCT04953559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
Study NCT04953559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
Study NCT05448105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care (MDC) Mobile
Description: My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
Study NCT06150274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Balloon Mitral Valvulotomy
Description: Stenotic mitral valve will be dilated to open the commissures
Study NCT05477563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
Study NCT04750564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study NCT04750564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: EStim will applied for 10 to 20 minutes.
Study NCT06328439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS014004
Description: Specification: 7.5mg; 30mg QD Oral
Study NCT05988372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
Description: Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
Study NCT05988372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel + Gemcitabine
Description: Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
Study NCT05424497 — intervention group
Intervention type: OTHER
Intervention: Vignettes
Description: Presenting vignettes with fictive cases
Study NCT04705701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
Study NCT04692987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision-aid video
Description: Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
Study NCT05854641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stempeucel®
Description: • Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Study NCT05600686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05600686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT05600686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05600686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV
Study NCT04659005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led decision counseling
Description: Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
Study NCT04659005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
Study NCT05600686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT05600686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05600686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT04787848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relistor Injectable Product
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Study NCT06339775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg).
Study NCT05114473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshops
Description: Several face-to-face workshops given by a researcher
Study NCT05114473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online-accessed material
Description: Access to a website containing the educational program
Study NCT06349811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M05D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT05658497 — intervention group
Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.
Study NCT05658497 — intervention group
Intervention type: DRUG
Intervention: Avonex
Description: Administered as specified in the treatment arm.
Study NCT05658497 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tysabri
Description: Administered as specified in the treatment arm.
Study NCT05658497 — intervention group
Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study NCT05702814 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study NCT06511453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure (using AcuWand or pencil eraser)
Description: The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure.
Study NCT06303505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-040
Description: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Study NCT04817761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase pegol (S95015)
Description: Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2.